摘要号:OA-15 标题:Maintenance Therapy Cessation for Multiple Myeloma Patients with Three-Year Sustained MRD Negative Remissions 中文标题:持续3年MRD阴性缓解的MM患者停止维持治疗 讲者:纪念斯隆凯特琳癌症中心 Neha Korde 研究介绍 来那...
2023年9月6日,中国医学科学院血液病医院(中国医学科学院血液学研究所)安刚教授、邹德慧教授、邱录贵教授团队在《Cancer Research Communications》期刊在线发布了题为“Clinical benefit of autologous stem cell transplantation for multiple my...
4. Annemiek Broijl, Augustinus C M de Jong, Mark van Duin, Pieter Sonneveld, JesperKühnau, Vincent H J van der Velden, VS38c and CD38-Multiepitope AntibodiesProvide Highly Comparable Minimal Residual Disease Data in Patients With MultipleMyeloma, American Journal of Clinical Pathology, Volume 15...
前言美国时间4月12日,FDA ODAC会议上通过了一项将微小残留病(minimal residual disease,MRD)作为多发性骨髓瘤(multiple myeloma, MM)的加速批准终点的议题。 PART 01 MM患者MRD检测的临床意义多发性骨髓瘤MM…
这将增加根据MRD缓解进行患者分层的准确性，以及比较治疗组之间和临床试验之间的MRD阴性率的准确性。参考文献 Bruno Paiva, Jesus F San-Miguel, Hervé Avet-Loiseau.MRD in multiple myeloma: does CR really matter? Blood (2022) 140 (23): 2423–2428. https://doi.org/10.1182/blood.2022016170 ...
Background: MRD assessment is a known surrogate marker for survival in multiple myeloma (MM). However, some patients with non-detectable MRD, do relapse, and some MRD-positive patients with an extensive follow-up, do not relapse. Clonal diversity is defined as the number of unique ...
Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences. Video Player is loading. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA...
5. P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION INDARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS
EP: 10.MRD Negativity in Multiple Myeloma EP: 11.The Value of MRD Testing in Lymphoid Malignancies Newsletter Stay up to date on the most recent and practice-changing oncology data Subscribe Now! Latest CMEView AllVideo Community Oncology Connections™: Community Oncologists’ Role in Selecting ...
[2] Valeria Ferla, Elena Antonini, Tommaso Perini, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.Front Oncol. 2022 Aug 16;12:932852. doi: 10.3389/fonc.2022.932852. ...